Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Giles Richard Platford is President, IBU at Takeda Pharmaceutical. OQRO lists 1 transaction filed with the SEC under this name, the latest on Nov 5, 2026, each linked to the official Form 4.
President, IBU
Disclosures on record
1
Companies involved
1
As of the latest filing on , Giles Richard Platford reported holding 270,253 shares of Takeda Pharmaceutical (TAK), worth about $5.79M at the last close of $21 (Nov 13, 2026). In the last 12 months, Giles Richard Platford sold $1.16M in 1 sale.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Takeda Pharmaceutical TAK | 270,253 | 270K direct | $21 | $5.79M | Nov 4, 2026 |
Is this Giles Richard Platford’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Nov 4, 2026Sold~$1.16Mdisclosed Nov 5
DetailsOfficial recordGiles Richard Platford has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
Giles Richard Platford reported 0 open-market purchases and 1 sale since 2026; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $1.16M1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 4, 2026, Giles Richard Platford reported holding 270,253 shares of Takeda Pharmaceutical (TAK). At the last close of $21 on Nov 13, 2026, that is about $5.79M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Giles Richard Platford reported 1 open-market sale worth $1.16M, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Giles Richard Platford has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
In SEC filings since 2026: no open-market purchase is on record; the latest open-market sale is from 2026.
Takeda Pharmaceutical (TAK), from 2026 to 2026: 0 purchases and 1 sale.
Giles Richard Platford reported 0 open-market purchases and 1 sale here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
